Protocol Ledger

NCT07225621 · Phase II · RECRUITING

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Interventional Phase II clinical trial protocol NCT07225621 sponsored by Alpheus Medical in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-28 Enrollment: 103 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07225621
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)103 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07225621
Protocol FieldVerified Registry Value
NCT IdentifierNCT07225621
Consolidated Lead SponsorAlpheus Medical
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment103 participants (ESTIMATED)
Registered Start Date2026-01-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07225621
Hospital Research SiteLocationSite Profile
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
Albany Medical CenterAlbany, NYOpen Hospital Dossier ->
Columbia University Irving Medical CenterNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI